Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome
Key facts
- Who runs it
- Timothy J Nelson, MD, PhD
- Where
- Aurora, Birmingham, Cincinnati, Los Angeles, Minneapolis, New Orleans, Oklahoma City, and Philadelphia, United StatesSee the 8 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 95 people enrolled
- Started
- 6 Jun 2019
- Ended
- Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Autologous (self) mononuclear cells derived from umbilical cord blood
- Stage II Surgical repair
- Record updated
- 8 July 2025
Who can take part
- Age
- Up to 12 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosis of HLHS or HLHS variant with single right ventricular dependent CHD having undergone Stage I surgical repair and undergoing Stage II surgical repair
- Less than 13 months of age at time of Stage II surgical repair
- Previous participation in the UCB collection protocol with autologous UCB-MNC product that is acceptable for use (treatment arm only)
Who cannot take part
- Any of the following complications of his/her congenital heart disease:; Any condition requiring urgent, or unplanned interventional procedure within 15 days prior to Stage II surgical repair, unless complete and full cardiac recovery is documented by site investigator; Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure); Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome, not directly related to the stem cell product or its injection procedure, during or after Stage II surgical repair
- History of DMSO reaction (treatment arm only)
- Severe chronic diseases at the discretion of the treating physician
- Extensive extra-cardiac syndromic features
- Known history of cancer
- Parent(s) and/or legal guardian(s) unwilling to have their child participate or unwilling to follow the study procedures
Where in United States
- Children's Hospital ColoradoAurora, United States
- Children's of AlabamaBirmingham, United States
- Cincinnati Children's Hospital and Medical CenterCincinnati, United States
- Children's Hospital of Los AngelesLos Angeles, United States
- Children's Hospitals of MinnesotaMinneapolis, United States
- Ocshner Medical CenterNew Orleans, United States
- Oklahoma University Medical CenterOklahoma City, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
Researchers want to better understand what happens to the heart when the stem cells are injected directly into the muscle of the right side of the heart during the Stage II palliative surgery for single ventricle patients with hypoplastic left heart syndrome (HLHS) or HLHS variant. Researchers want to see if there are changes in the heart's structure/function following this stem cell-based therapy and compared to children that have not had cell-based therapy.
The 2 groups in the trial
- TreatmentTreatment being tested
Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
Treatment: Autologous (self) mononuclear cells derived from umbilical cord blood and Stage II Surgical repair
- ControlExisting treatment, for comparison
Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
Treatment: Stage II Surgical repair
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)
- Publications
- Record updated
- 8 July 2025